Senti Biosciences (NASDAQ:SNTI) Shares Down 3.6% – Here’s Why

Senti Biosciences, Inc. (NASDAQ:SNTI) traded down 3.6% during mid-day trading on Wednesday . The company traded as low as $1.03 and last traded at $1.06. Approximately 75,015 shares were traded during trading, a decline of 56% from the average daily volume of 172,147 shares. The stock had previously closed at $1.10.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SNTI. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, March 28th. Chardan Capital boosted their price target on shares of Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Senti Biosciences currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Senti Biosciences Stock Performance

The company has a market cap of $33.02 million, a PE ratio of -0.55 and a beta of 2.04. The company has a 50 day simple moving average of $0.99 and a two-hundred day simple moving average of $0.99.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.22. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. As a group, analysts expect that Senti Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Armistice Capital LLC bought a new position in Senti Biosciences in the 2nd quarter worth approximately $1,883,000. Geode Capital Management LLC boosted its position in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Senti Biosciences during the third quarter valued at approximately $117,000. Virtu Financial LLC acquired a new stake in Senti Biosciences in the 4th quarter valued at $46,000. Finally, Jane Street Group LLC bought a new stake in shares of Senti Biosciences in the 4th quarter worth about $40,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.